Combined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in 2021 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development ...
Author(s)Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, ...
REYKJAVIK, Iceland, July 20, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
REYKJAVIK, Iceland, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results